Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib plus endocrine therapy and goserelin in premenopausal women with HR-positive, HER2-negative advanced breast cancer
2014-001931-36Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Ribociclib + endocrine therapy + goserelin with Placebo + endocrine therapy + goserelin (2 arms). Primary endpoint: Progression-free survival. Started Oct 2014; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-001931-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001931-36.